Work Here?
Industries
Industrial & Manufacturing
Biotechnology
Company Size
201-500
Company Stage
Series C
Total Funding
$355M
Headquarters
South San Francisco, California
Founded
2019
Cellares focuses on developing and manufacturing cell therapies within the biotechnology sector. The company operates as an Integrated Development and Manufacturing Organization (IDMO), which means it combines the development and manufacturing processes of cell therapies in one facility, unlike traditional organizations that keep these processes separate. Cellares utilizes its proprietary "Smart Factory" technology, which features an automated single-use cartridge system. This system significantly enhances productivity, reduces costs per batch, and lowers process failure rates compared to conventional methods. Cellares serves a diverse clientele, including preclinical, clinical, and commercial entities, and has partnered with major pharmaceutical companies to automate the manufacturing of CAR-T cell therapies. The company aims to provide efficient and cost-effective manufacturing services, making it a competitive choice for businesses in the cell therapy space.
💡 Want to apply to Cellares?
You have ways to get a Cellares referral from your network.
Get referrals →
Help us improve and share your feedback! Did you find this helpful?
Total Funding
$355M
Above
Industry Average
Funded Over
3 Rounds
Industry standards
Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
Stock Options
bluebird bio announced on 21 February 2025 that it had entered into a definitive agreement to be acquired global investment firms Carlyle (DC, USA) and SK Capital (NY, USA) for US$3.00 per share in cash, plus a contingent value right of $6.84 per share if certain sales targets are met.
Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.
Cellares, a Bridgewater-based leader in automated cell therapy manufacturing, on Monday announced it appointed Ossama Eissa, former executive at Novartis, Lonza Biologics, and Legend Biotech, as chief operating officer.Eissa’s extensive experience will support the expansion of Cellares’ Smart Factory network in the United States, Europe, Japan and other international markets, addressing the challenges of scalability, cost, and quality that have long hindered patient access. Through these advancements, Cellares will work to ensure that life-saving treatments are accessible for oncology and autoimmune patients globally.This appointment strengthens the Cellares leadership team in a time of rapid global expansion of the company’s IDMO manufacturing services, in response to the growing global demand for cell therapy manufacturing capacity.Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing.He formerly served as vice president and general manager at Legend Biotech, where he led the Raritan production site through the global launch of Carvykti, a CAR-T cell therapy.At Lonza Biologics, Eissa managed Global Strategic Projects, contributing significantly to the Cell and Gene Technologies Business Unit by boosting manufacturing efficiency and driving commercial scale-up. He also oversaw U.S. manufacturing operations at Novartis, scaling production and supporting regulatory approval for Kymriah, the first FDA-approved CAR-T cell therapy.“Joining Cellares is an opportunity to address one of the biggest challenges in healthcare today: making cell therapies accessible to all of those who need them,” Eissa said. “The mission aligns closely with my experience in scaling complex manufacturing systems to benefit patients directly. I’ve witnessed the profound impact these treatments have, and I’m committed to ensuring that we reach more patients, especially those facing cancer and autoimmune diseases, with the reliability and speed they deserve.”
Self-acclaimed integrated development and manufacturing organization (IDMO) Cellares has partnered with Sony Corporation, a technology firm focused on the field of flow cytometry, to integrate advanced flow cytometry-based cell analysis and sorting solutions into the Cellares Cell Shuttle platform.
Cellares, a leader in cell therapy manufacturing and an Integrated Development and Manufacturing Organization (IDMO), has appointed Justin McAnear as Chief Financial Officer (CFO) and Jonathan Butler as General Counsel and Corporate Secretary (GC).
$90k - $210k/yr
Bridgewater Township, NJ, USA
$90k - $210k/yr
Bridgewater Township, NJ, USA
Find jobs on Simplify and start your career today
People & HR
1 Open Roles
Discover companies similar to Cellares
Industries
Industrial & Manufacturing
Biotechnology
Company Size
201-500
Company Stage
Series C
Total Funding
$355M
Headquarters
South San Francisco, California
Founded
2019
$140k - $240k/yr
Bridgewater Township, NJ, USA
$90k - $210k/yr
Bridgewater Township, NJ, USA
$90k - $210k/yr
Bridgewater Township, NJ, USA
Find jobs on Simplify and start your career today
People & HR
1 Open Roles
Discover companies similar to Cellares